Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive global study reveals hidden burden of kidney disease in dialysis patients

NCT ID NCT07607002

Knowledge-focused Sponsor: Arbor Research Collaborative for Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at information from about 70,000 adults receiving hemodialysis around the world to find out how many have IgA nephropathy (a type of kidney disease) and how it affects their health. Researchers compared patients with IgA nephropathy to other dialysis patients to measure the extra burden of this condition. The goal was to better understand the disease's impact, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70,000 people

The number who actually took part.

Started

Jan 1996

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a retrospective observational study using data from Phases 1 through 7 (1996-2023) of the DOPPS, a multinational, prospective cohort study of in-center HD patients across more than 20 countries. DOPPS collects standardized data on demographics, comorbidities, laboratory values, treatments, hospitalizations, and mortality, as well as many validated PROs. To ensure national representativeness and reduce selection bias, DOPPS uses a stratified random sampling approach to select dialysis facilities and patients within each participating country. Regional representation includes Europe, Japan, North America, China, Oceania, and the Gulf Cooperation Council (GCC).

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years at the time of enrollment * Receiving in-center HD treatment at a participating dialysis facility * Able to provide informed consent, if required by local regulations or ethics boards Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Igan - IgA nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Igan - IgA nephropathy

More trials for these conditions

Other studies related to the condition(s) this trial covers.